Pacira Pharmaceuticals (PCRX) Posts Q2 Loss of 27c/Share

Pacira Pharmaceuticals (NASDAQ: PCRX) reported Q2 EPS of ($0.27), $0.16 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $12.3 million versus the consensus estimate of $8.77 million.

For earnings history and earnings-related data on Pacira Pharmaceuticals (PCRX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• Schwab's May activity shows margin loans nearly double
• Carvana (CVNA) PT Lowered to $85 at RBC Capital